FDA Approves OTC Sale of Pataday (Olopatadine Solution) Eye Allergy Drops

 FDA Approves OTC Sale of Pataday (Olopatadine Solution) Eye Allergy Drops

Alcon has announced the Food and Drug Administration (FDA) approval for the U.S. over the counter (OTC) sale of two eye allergy medications: Pataday Once Daily Relief® (olopatadine solution 0.2%) and Pataday Twice Daily Relief® (olopatadine solution 0.1%).

Pataday Once Daily Relief (olopatadine hydrochloride ophthalmic solution 0.2%) and Pataday Twice Daily Relief (olopatadine hydrochloride ophthalmic solution 0.1%) are indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander for ages 2 and older. Pataday Twice Daily Relief (olopatadine 0.1%) is also indicated for the temporary relief of red eyes. Since 2008, over 40 million prescriptions have been written for olopatadine, the active ingredient in Pataday.

The rights to the Rx-to-OTC switch were secured by Alcon as part of its separation from Novartis in April 2019. Alcon will market both Patanol Solution (olopatadine 0.1%) and Pataday Solution (olopatadine 0.2%) under the Pataday brand name as Pataday Twice Daily Relief and Pataday Once Daily Relief, respectively. Both strengths provide long-lasting, itchy eye relief that works in minutes.

Approximately 66 million Americans (1 in 5) suffer from ocular allergies, but only 7 million use an over-the-counter allergy eye drop to relieve their symptoms. By making Pataday (0.1% and 0.2%) available over the counter, more Americans will have access to long-lasting, prescription-strength relief from the itching associated with eye allergies.

U.S. commercial availability of Pataday Once Daily Relief and Pataday Twice Daily Relief will begin March 2 in time for the start of spring allergy season, and will be available in all major drug, food and mass market retailers – more than 40,000 stores – as well as through online retailers. The launch is supported by a multimillion-dollar media plan including a national TV advertising campaign and strong online presence to reach eye allergy sufferers.

Full news release: https://www.businesswire.com/news/home/20200217005063/en/4709989/Alcon-Launch-Pataday-Eye-Allergy-Drop-1

Source: Alcon

  • <<
  • >>

Comments